2. Academic Validation
  3. Identification of a novel benzyloxy-terminated scaffold as a potent and selective TYK2 inhibitor for anti-inflammatory therapy

Identification of a novel benzyloxy-terminated scaffold as a potent and selective TYK2 inhibitor for anti-inflammatory therapy

  • Eur J Med Chem. 2026 Jan 5:301:118211. doi: 10.1016/j.ejmech.2025.118211.
Yang Tian 1,  Yanzhuo Liu 2,  Jianyu Liu 2,  Jing Luo 1,  Jingwen Zhang 1,  Xiong Zhang 1,  Hengkang He 1,  Yixi Xiao 1,  Jianhui Zhang 3,  Tao Yang 4
Affiliations

Affiliations

  • 1 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, 610014, Sichuan, China; Medical Research Center, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, 610031, Sichuan, China.
  • 2 Medical Research Center, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, 610031, Sichuan, China.
  • 3 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, 610014, Sichuan, China. Electronic address: [email protected].
  • 4 National Chengdu Center for Safety Evaluation of Drugs, West China Hospital of Sichuan University, Chengdu, 610041, China. Electronic address: [email protected].
PMID: 41072266 DOI: 10.1016/j.ejmech.2025.118211
Abstract

In this study, we described three series of N-phenylpyrimidin-2-amine derivatives as selective Tyk2 inhibitors. Systematic exploration of the structure-activity relationship through the introduction of an O-linker and the flexible benzyl substituent based on the reported non-selective JAKs inhibitor yt52 led to the discovery of the optimized derivative compound 29i. Compound 29i showed a potency on Tyk2 with an IC50 value of 18 nM and exhibited more than >70-fold selectivity over JAK1/2/3 isoforms. Kinase panel screening, WB assays, and human peripheral blood mononuclear cell assays further validated the selectivity of compound 29i. Compound 29i demonstrated pharmacokinetic properties with an oral bioavailability of 42.7 %. Moreover, in models of inflammatory disease (allergic rhinitis) and autoimmune disease (alopecia areata), compound 29i demonstrated comparable therapeutic effects to market drugs. Taken together, these findings establish that compound 29i is a selective Tyk2 Inhibitor with compelling potential for clinical development.

Figures
Products